Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

Abstract Background In 2014 and 2015, biosimilars for the drugs filgrastim, infliximab, and insulin glargine were approved for use in Canada. The introduction of biosimilars in Canada could provide significant cost savings for the Canadian healthcare system over originator biologic drugs, however it...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kerry Mansell (Author), Hishaam Bhimji (Author), Dean Eurich (Author), Holly Mansell (Author)
Formato: Livro
Publicado em: BMC, 2019-11-01T00:00:00Z.
Assuntos:
Acesso em linha:Connect to this object online.
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

Connect to this object online.

3rd Floor Main Library

Detalhes do Exemplar 3rd Floor Main Library
Área/Cota: A1234.567
Cód. Barras: 1 Disponível